

Adaptimmune Therapeutics plc (Wed, May 01, 2024)

Sell candidate since May 01, 2024

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-1.43**
#12026/ 30053

Trend: Sell
MV Long: Sell
MV Short: Buy
Pivot: Buy
Volume: Buy
MACD: Buy

Tech commentaries:

The **Adaptimmune Therapeutics plc** stock price gained **1.68%** on the last trading day (Wednesday, 1st May 2024), rising from **\$1.19** to **\$1.21**. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated **7.76%** from a day low at **\$1.16** to a day high of **\$1.25**. The price has risen in 7 of the last 10 days and is up by **22.59%** over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **256 thousand** more shares were traded than the day before. In total, **911 thousand** shares were bought and sold for approximately **\$1.10** million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-13.61%** during the next 3 months and, with a 90% probability hold a price between **\$0.744** and **\$1.38** at the end of this 3-month period.

A buy signal was issued from a pivot bottom point on **Thursday, April 18, 2024**, and so far it has risen 34.68%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). **Adaptimmune Therapeutics plc** has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Adaptimmune Therapeutics plc** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$1.28**. On a fall, the stock will find some support from the short-term average at **\$1.13**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Adaptimmune Therapeutics plc finds support from accumulated volume at **\$1.17** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at **\$1.33**, **\$1.38** and **\$1.44**.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved **\$0.0900** between high and low, or **7.76%**. For the last week, the stock has had daily average volatility of **7.47%**.

Adaptimmune Therapeutics plc holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: Very High

Evaluation: Sell Candidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.